Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-157 in head and neck squamous cell cancer
NCT05312710Phase 2Active, not recruiting
- Sponsor
- Aveta Biomics
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of APG-157 in head and neck squamous cell carcinoma (HNSCC), sponsored by Aveta Biomics. Primary endpoint: Tumor Size by Imaging at 6 weeks. Started Apr 2022; status: active, not recruiting.
02
Drugs
APG-157
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05312710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312710.